Emcure Pharmaceuticals Ltd Share Price

India Pharma Market Grows 12.1% in July, Led by Zydus Lifesciences and Sun Pharma

India’s pharmaceutical market grew 12.1% year-on-year in July 2026, marking a strong recovery after subdued growth. According to Analyst latest note, the market has maintained double-digit growth, supported by price increases, new product launches and improving volumes. Sales growth in July was driven by a 6% increase in prices. The recovery was supported by a favourable low volume base, higher contributions from new launches such as GLP-1 drugs, and stronger demand across chronic therapies, including cardiac and neurological treatments, as well as VMNs and oncology. Zydus Lifesciences and Sun Pharma recorded the strongest year-on-year growth in July in value terms. On a moving annual total basis, Torrent Pharma led growth at 14.4%, followed by Glenmark and Zydus Lifesciences at 14.2% each. Among major therapy segments, anti-diabetes recorded the fastest growth in July, followed by vitamins, minerals and nutrients (VMNs). Anti-diabetes growth was largely driven by new product launches, with GLP-1 therapies accounting for around 48% of the segment’s growth. VMN growth, meanwhile, was primarily price-led. Cardiac, respiratory, pain, neurology and gynaecology therapies also posted double-digit growth. In contrast, gastro, anti-infectives and dermatology witnessed muted single-digit growth, mainly due to weak volume growth, according to Pharmarack data. At the company level, IPCA Laboratories benefited from strong double-digit growth in pain and cardiology, although weakness in anti-malaria and anti-infective products weighed on overall performance. Growth was relatively subdued for Mankind Pharma, Emcure.

See More

Update for investors of

Pharma

is currently trading at Rs. 1987.10, up by 10.00 points or 0.51% from its previous closing of Rs. 1977.10 on the BSE. The scrip opened at Rs. 2007.65 and has touched a high and low of Rs. 2047.40 and Rs. 1,980.15 respectively. So far 5703 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 2,047.40 on 10-Aug-2026 and a 52 week low of Rs. 1260.10 on 30-Sep-2025. Last one week high and low of the scrip stood at Rs. 2,047.40 and Rs. 1911.15 respectively. The current market cap of the company is Rs. 37822.22 crore. The promoters holding in the company stood at 77.83%, while Institutions and Non-Institutions held 13.34% and 8.83% respectively. Emcure Pharmaceuticals has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) following an inspection of its formulations manufacturing facility in Sanand, Ahmedabad, Gujarat. The USFDA conducted this inspection from May 06, 2026 to May 15, 2026. The USFDA has classified the inspection status of the said facility as Voluntary Action Indicated (VAI) and accordingly, the inspection stands closed. Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.

See More

Emcure Pharmaceuticals Shares in Focus After USFDA Inspection Closure

Emcure Pharmaceuticals shares are likely to remain in focus on August 10 after the company received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its formulations facility in Sanand, Gujarat. The EIR follows an inspection conducted between May 6 and May 15, 2026, with the USFDA classifying the inspection as Voluntary Action Indicated (VAI). The inspection has now been closed. Analysts have raised their earnings estimates for Emcure Pharmaceuticals, citing strong growth in its antiretroviral (ARV) order book in rest-of-world markets, continued expansion of its European business and increasing efforts in the domestic formulations segment. The positive outlook reflects expectations of sustained business growth across key markets. For the June quarter, Emcure Pharmaceuticals reported a 36.2% year-on-year increase in consolidated net profit to ₹292 crore, while revenue from operations rose 22.8% to ₹2,580 crore. EBITDA increased 25.8%, with the margin improving to 19.7%. Shares closed at ₹1,977.10 in the previous session, up 2.12%, and are trading close to their 52-week high.

See More

Indian Market Insights – 10 August 2026

Indian equity markets are expected to remain in a consolidation phase with a neutral bias on the daily charts, while healthy sector rotation continues to support the broader market structure. The overall trend remains constructive, and a buy-on-dips approach can be considered as long as key support levels are protected. On the technical front, Nifty has strong intraday support in the 24,400–24,420 zone. Holding this area can keep the index positive and support a move towards 24,700–24,750, which remains the key resistance zone. A sustained breakout above this range could improve momentum further. Bank Nifty has also remained range-bound over the past few sessions and is likely to continue consolidating in today’s trade. Key support is placed around 57,100–57,250, while immediate resistance is seen at 58,200–58,250, followed by 58,500. From the derivatives perspective, FIIs created fresh short positions during Friday’s session, so today’s closing price action will be important. Traders should closely monitor whether these shorts continue to build or start getting covered, as this could influence the next directional move. Key Cues for Today Positive: Strong U.S. jobs data could support global risk sentiment. Negative: Rising crude oil prices remain a concern, particularly for oil-importing economies like India, as higher crude can impact inflation and corporate margins. Stocks to Watch

, Oil India, Signature Global, Emcure Pharma, RITES, Anaview Wire, Anant Raj, Nitin Spinners, Akums Drugs and Ambika Cotton will remain in focus today. Overall Strategy: Keep a positive bias above key supports, prefer buying on dips, and avoid aggressive positions while Nifty and Bank Nifty remain within their current ranges.

See More

Emcure Pharma Receives US FDA Approval for Gujarat Plant

💊

has received US FDA approval for its formulations manufacturing facility in Sanand, Gujarat, marking a significant regulatory milestone for the company. The approval strengthens Emcure's manufacturing capabilities and supports its presence in the regulated US pharmaceutical market.

See More

Emcure Pharmaceuticals Q1 Profit Jumps 42% on Strong Revenue and Margin Growth

Research Analyst: UJVIN NEVATIA (PROPRIETOR: NEVAT INVESTMENTS) | SEBI Registration No.: INH100009628

reported a robust performance for the first quarter of FY27, with consolidated net profit rising 42% year-on-year to ₹294 crore from ₹207 crore in the corresponding quarter last year. Revenue from operations increased 22.8% to ₹2,580 crore, driven by healthy growth across its domestic and international pharmaceutical businesses. The company's operating performance also strengthened during the quarter. EBITDA grew 27.8% year-on-year to ₹533 crore from ₹417 crore, while the EBITDA margin expanded by 90 basis points to 20.7% from 19.8% a year ago, reflecting improved operational efficiency and a favourable product mix. The board also appointed Satish Mehta, the company's CEO and founder, as Chairman. Industry & Economic Impact: The results highlight the continued strength of India's pharmaceutical sector, supported by growing demand for branded formulations, specialty medicines, and exports. Higher revenue and margin expansion indicate improving operational efficiency and sustained demand across key therapeutic segments. From an economic perspective, sustained growth in pharmaceutical manufacturing supports exports, research and development, skilled employment, and healthcare innovation. Continued expansion by companies like Emcure Pharmaceuticals strengthens India's position as a global pharmaceutical manufacturing hub and contributes to long-term industrial and economic growth. Source: NDTV Profit No Recommendations

See More